{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"171-084-618-956-808","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"171-084-618-956-808","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":7009,"type":"PATENT","title":"Walter and Eliza Hall Institute of Medical Research Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1417,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8705,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants= ' Walter and Eliza Hall Institute of Medical Research' ' Walter and Eliza Hall Institute' ' Walter and Eliza Hall Inst'
Select more for logical variants
Add to collection
Search Owners(US) = Walter and Eliza Hall Institute of Medical Research' ' Walter and Eliza Hall Institute' ' Walter and Eliza Hall Inst'
Select more for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents= 765
..........Annie Second Search.......
Search applicants and Owners(US) respectively = Wal* Eli* Ha* Inst* Med* Res*, Wa* AND El* Ha* Inst* Med* Res*,Wa* And El* Ins* Med* Res*, Wa* El* Ins* Med*
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents= 866
Search Applicants= ' Walter and Eliza Hall Institute of Medical Research' ' Walter and Eliza Hall Institute' ' Walter and Eliza Hall Inst'
Select more for logical variants
Add to collection
Search Owners(US) = Walter and Eliza Hall Institute of Medical Research' ' Walter and Eliza Hall Institute' ' Walter and Eliza Hall Inst'
Select more for logical variants
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents= 765
..........Annie Second Search.......
Search applicants and Owners(US) respectively = Wal* Eli* Ha* Inst* Med* Res*, Wa* AND El* Ha* Inst* Med* Res*,Wa* And El* Ins* Med* Res*, Wa* El* Ins* Med*
Add to collection
Select all the patents in the collection and expand by simple families
Add to collection
Total patents= 866
(a) providing a tissue sample from a patient;\n
(b) determining if expression of a Bcl-xL gene is amplified relative to a baseline control level determined before the administration of N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide;\n
(c) identifying the patient as eligible to receive N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or the anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL if the Bcl-xL gene is not amplified; and\n
(d) administering N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or the anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL to the patient identified as being eligible to receive N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or the anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein amplification of the Bcl-xL gene correlates with an increase in expression of Bcl-xL polypeptide."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the tissue sample comprises a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a lymph node sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample, a paraffin embedded tissue sample or an extract or processed sample produced from any of a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample or a paraffin embedded tissue sample."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the determining step comprises in situ hybridization."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the in situ hybridization is performed with a nucleic acid probe that is detectably labeled."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the in situ hybridization is performed with a nucleic acid probe or peptide nucleic acid probe that specifically hybridizes to at least part of the Bcl-xL gene."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein determining comprises a polymerase chain reaction."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the polymerase chain reaction is performed with at least one primer that specifically hybridizes to at least part of a nucleic acid sequence of the Bcl-xL gene."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the determining step comprises a nucleic acid microarray assay."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A method for identifying a patient with small-cell lung carcinoma or a lymphoma as eligible to receive N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide therapy or an anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL comprising:\n
(a) providing a test sample from a patient;\n
(b) determining in the test sample:\n\n(i) if a Bcl-xL gene is amplified relative to a baseline control level determined before the administration of N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide; and\n(ii) an amount of Bcl-xL in the test sample;\n
(c) determining if the amount of Bcl-xL in the test sample is higher or lower than the amount of Bcl-xL in a control, wherein the control is a level determined before the administration of N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl) sulfonyl)benzenesulfonamide; and\n
(d) identifying the patient as eligible to receive N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or the anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL therapy based on:\n\n(i) amplification of the Bcl-xL gene; and\n(ii) the amount of Bcl-xL is higher in the test sample than in the control; and\n
(e) administering N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or the anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL to the patient identified as being eligible to receive N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or the anti-sense agent designed to bind to one of Bcl-2, Bcl-w, and Bcl-xL."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the test sample comprises a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a lymph node sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample, a paraffin embedded tissue sample or an extract or processed sample produced from any of a peripheral blood sample, a tumor tissue or a suspected tumor tissue, a thin layer cytological sample, a fine needle aspirate sample, a bone marrow sample, a urine sample, an ascites sample, a lavage sample, an esophageal brushing sample, a bladder or lung wash sample, a spinal fluid sample, a brain fluid sample, a ductal aspirate sample, a nipple discharge sample, a pleural effusion sample, a fresh frozen tissue sample or a paraffin embedded tissue sample."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein determining amplification of the Bcl-xL gene comprises in situ hybridization."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 12, wherein the in situ hybridization is performed with a nucleic acid probe that is detectably labeled."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 12, wherein the in situ hybridization is performed with a nucleic acid probe or peptide nucleic acid probe that specifically hybridizes to at least part of the Bcl-xL gene."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein determining amplification of the Bcl-xL gene comprises a polymerase chain reaction."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the polymerase chain reaction is performed with at least one primer that specifically hybridizes to at least part of a nucleic acid sequence of the Bcl-xL gene."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the determining step comprises a nucleic acid microarray assay."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the determining step (b)(ii) is performed by immunoassay."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the immunoassay is a sandwich immunoassay."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the immunoassay is an ELISA."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the determining step (b)(ii) is performed on an automated immunoassay instrument."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the determining step (b)(ii) is performed by measuring Bcl-xL mRNA."],"number":22,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}